<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebral <z:hpo ids='HP_0000006'>autosomal-dominant</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CADASIL) is a vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> arising from abnormal arteriolar vascular smooth muscle cells </plain></SENT>
<SENT sid="1" pm="."><plain>CADASIL results from mutations in Notch3 that alter the number of <z:chebi fb="0" ids="32460">cysteine residues</z:chebi> in the extracellular epidermal growth factor-like repeats, important for ligand binding </plain></SENT>
<SENT sid="2" pm="."><plain>It is not known whether CADASIL mutations lead to loss or gain of Notch3 receptor function </plain></SENT>
<SENT sid="3" pm="."><plain>To examine the functional consequences of CADASIL mutations, we engineered 4 CADASIL-like mutations into rat Notch3 and have shown that the presence of an unpaired cysteine does not impair cell-surface expression or ligand binding </plain></SENT>
</text></document>